Skip to main content

Table 6 Median dose and relative confidential interval values of gemcitabine alone and in combination with EGFR/HER2 pathway inhibitors on BTC cell lines.

From: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Dm μM (confidence interval) TFK-1 CI* EGI-1 CI* HuH28 CI* TGBC1-TKB CI*
Gemcitabine (Gem) 0.1   0.00074   > 10   0.28  
  (0.003-2.93)   (0.0002-0.002)     (0.12-0.43)  
Gem + erlotinib 0.04 0.11 0.00017 0.56 > 10 0.5 0.24 0.8
  (0.03-0.73)   (0.00006-0.0005)     (0.033-2.28)  
Gem + gefitinib 0.08 0.15 0.00004 0.15 2.9 0.9 0.26 0.9
  (1.1-2.9)   (0.0000007-0.002)   (0.15-5.3)   (0.13-0.53)  
Gem + lapatinib 0.07 0.36 0.03   2.01 1.5 0.13 0.6
  (0.09-29.01)   (0.006-0.17)   (0.46-8.6)   (0.06-0.27)  
Gem + sorafenib 0.07 0.017 0.01 0.19 > 10   0.11 0.062
  (0.000009-0.31)   0.00019-1.07)     (0.05-0.23)  
Gem + everolimus 0.03 0.15 0.00057 0.015 > 10   0.001 0.07
  0.004-0.43)   (0.00002-0.01)     (0.00007-0.022)  
  1. *CI = combination index indicates synergism when <1